Hostname: page-component-77c89778f8-gvh9x Total loading time: 0 Render date: 2024-07-18T10:19:46.908Z Has data issue: false hasContentIssue false
  • English
  • Français

The influence of psychopharmacological treatment in the long-term outcome in patients suffering ADH with comorbid drug use

Published online by Cambridge University Press:  23 March 2020

L.A. Núñez Domínguez ,
A. Portilla Fernández ,
L. Reula ,
E. Manrique Astiz ,
O. Arbeo Ruiz ,
M. García Nicolás  and
O. Fernández de la Vega
L.A. Núñez Domínguez*
Affiliation:
Centro Médico, Psychiatry, Pamplona, Spain
A. Portilla Fernández
Affiliation:
Hospital de Día, Psychiatry, Pamplona, Spain
L. Reula
Affiliation:
Clínica de Rehabilitación, Psychiatry, Pamplona, Spain
E. Manrique Astiz
Affiliation:
Mental Health Center, Psychiatry, Tafalla, Spain
O. Arbeo Ruiz
Affiliation:
Centro de Día Zuría, Psychiatry, Pamplona, Spain
M. García Nicolás
Affiliation:
Menatl Health Center, Psychiatry, Tudela, Spain
O. Fernández de la Vega
Affiliation:
Menatl Health Center, Psychiatry, Pamplona, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

ADH is one of mental disease with a higher prevalence of alcohol and drug abuse. ADH is a risk factor for drug use, and that's true in the reverse sense. The mutual influence in both disorders is clear and the presence of both disorders together could be a real challenge for a clincial professional.

The main objective of the study is to evaluate the influence of the psychopharmacological treatment in the longterm outcome of this sample, using a measurement drug use, adherence to the treatment and impulsivity.

We make a study that includes a group of patients with both disorders. We select a sample from the Centro de Día Zuría. The patients complete a battery of scales (SCL-90, BArratt, SF-36) before and after the beginning of psychopharmacological treatment.

Our results shows a better prognosis in the patients with a good adherence to treatment, with a decrease in frequency and levels of drug use and a decrease in impulsivity, with a low level of behavioral disorders and violence.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV387
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S382
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.